Literature DB >> 7619979

Clozapine decreases smoking in patients with chronic schizophrenia.

J McEvoy1, O Freudenreich, M McGee, C VanderZwaag, E Levin, J Rose.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7619979     DOI： 10.1016/0006-3223(94)00365-A

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN： 0006-3223            Impact factor:   13.382


× No keyword cloud information.
  41 in total

1.  Olanzapine vs. risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes.

Authors:  Serge Sevy; Delbert G Robinson; Suzanne Sunday; Barbara Napolitano; Rachel Miller; Joanne McCormack; John Kane
Journal:  Psychiatry Res       Date:  2011-06-01       Impact factor: 3.222

Review 2.  The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.

Authors:  Corinne Beinat; Samuel D Banister; Marco Herrera; Vivian Law; Michael Kassiou
Journal:  CNS Drugs       Date:  2015-07       Impact factor: 5.749

Review 3.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 4.  Clozapine dose for schizophrenia.

Authors:  Selvizhi Subramanian; Birgit A Völlm; Nick Huband
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

5.  Nicotinic modulation of salience network connectivity and centrality in schizophrenia.

Authors:  Jason Smucny; Korey P Wylie; Eugene Kronberg; Kristina T Legget; Jason R Tregellas
Journal:  J Psychiatr Res       Date:  2017-02-03       Impact factor: 4.791

6.  IV nicotine self-administration in rats using a consummatory operant licking response: sensitivity to serotonergic, glutaminergic and histaminergic drugs.

Authors:  Vanessa Cousins; Jed E Rose; Edward D Levin
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-06-20       Impact factor: 5.067

Review 7.  Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.

Authors:  Edward D Levin; Amir H Rezvani
Journal:  Biochem Pharmacol       Date:  2007-07-20       Impact factor: 5.858

8.  Ketanserin, a 5-HT2 receptor antagonist, decreases nicotine self-administration in rats.

Authors:  Edward D Levin; Susan Slade; Michael Johnson; Ann Petro; Kofi Horton; Paul Williams; Amir H Rezvani; Jed E Rose
Journal:  Eur J Pharmacol       Date:  2008-10-17       Impact factor: 4.432

Review 9.  Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors:  Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

Review 10.  Clozapine plasma level monitoring: current status.

Authors:  T B Cooper
Journal:  Psychiatr Q       Date:  1996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.